MY CONTENT

The authors evaluated the results reported in 23 studies that included 516 patients in whom different drugs were used for rescue therapy in thromboembolic complications during endovascular treatment of intracranial aneurysms. The literature shows that rescue therapy with thrombolytic agents resulted in significantly more morbidity than rescue therapy with glycoprotein IIb/IIIa inhibitors. Tirofiban/eptifibatide resulted in significantly higher recanalization rates compared with abciximab.